Baidu
map

FDA批准非药物疗法NeuroMetrix治疗纤维肌痛,是一种创新神经调节医疗器械

2022-06-17 MedSci原创 MedSci原创

FDA

 

图片

 

纤维肌痛是一种以全身疼痛、疲劳、睡眠不佳、记忆和注意力障碍、情绪障碍等致残症状为特征的慢性病。该类患者的健康相关生活质量较低,住院的可能性是没有纤维肌痛患者的两倍。此外,纤维肌痛的病因尚不清楚,但科学研究指出,这可能与中枢神经系统处理正常感觉和疼痛的方式异常有关。目前,针对纤维肌痛的治疗方式多为药物治疗,而NeuroMetrix开发的Quell是一种经皮神经电刺激设备(TENS),以非入侵的方式帮助具有高度疼痛敏感性的成人减轻纤维肌痛症状,该设备可在睡眠期间使用。5月19日,NeuroMetrix宣布Quell获FDA批准上市,Quell的批准得到一项双盲、随机、含假治疗对照的临床试验的支持。临床试验结果显示,在对所有受试者(N=119)的意向治疗(ITT)分析中,多个次要终点指标均为阳性。

本文盘点的几款诊疗设备为疾诊断提供了新的技术手段,为疗法创新提供了新的思路,也为医药行业注入了新的生机与活力,此外,还有更多医疗器械与诊断公司正在积极探索诊疗新方式,提升患者健康相关生活质量。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1839973, encodeId=f02c18399e366, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Nov 15 09:06:53 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034297, encodeId=8d91203429e28, content=<a href='/topic/show?id=33d28e81604' target=_blank style='color:#2F92EE;'>#药物疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87816, encryptionId=33d28e81604, topicName=药物疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sun Sep 18 06:06:53 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897022, encodeId=bea6189e0223d, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Tue Jul 26 18:06:53 CST 2022, time=2022-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286113, encodeId=660612861131d, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Jun 18 20:06:53 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226954, encodeId=a45d1226954c7, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Fri Jun 17 07:05:45 CST 2022, time=2022-06-17, status=1, ipAttribution=)]
    2022-11-15 bugit
  2. [GetPortalCommentsPageByObjectIdResponse(id=1839973, encodeId=f02c18399e366, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Nov 15 09:06:53 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034297, encodeId=8d91203429e28, content=<a href='/topic/show?id=33d28e81604' target=_blank style='color:#2F92EE;'>#药物疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87816, encryptionId=33d28e81604, topicName=药物疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sun Sep 18 06:06:53 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897022, encodeId=bea6189e0223d, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Tue Jul 26 18:06:53 CST 2022, time=2022-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286113, encodeId=660612861131d, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Jun 18 20:06:53 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226954, encodeId=a45d1226954c7, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Fri Jun 17 07:05:45 CST 2022, time=2022-06-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1839973, encodeId=f02c18399e366, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Nov 15 09:06:53 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034297, encodeId=8d91203429e28, content=<a href='/topic/show?id=33d28e81604' target=_blank style='color:#2F92EE;'>#药物疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87816, encryptionId=33d28e81604, topicName=药物疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sun Sep 18 06:06:53 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897022, encodeId=bea6189e0223d, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Tue Jul 26 18:06:53 CST 2022, time=2022-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286113, encodeId=660612861131d, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Jun 18 20:06:53 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226954, encodeId=a45d1226954c7, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Fri Jun 17 07:05:45 CST 2022, time=2022-06-17, status=1, ipAttribution=)]
    2022-07-26 一闲
  4. [GetPortalCommentsPageByObjectIdResponse(id=1839973, encodeId=f02c18399e366, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Nov 15 09:06:53 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034297, encodeId=8d91203429e28, content=<a href='/topic/show?id=33d28e81604' target=_blank style='color:#2F92EE;'>#药物疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87816, encryptionId=33d28e81604, topicName=药物疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sun Sep 18 06:06:53 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897022, encodeId=bea6189e0223d, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Tue Jul 26 18:06:53 CST 2022, time=2022-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286113, encodeId=660612861131d, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Jun 18 20:06:53 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226954, encodeId=a45d1226954c7, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Fri Jun 17 07:05:45 CST 2022, time=2022-06-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1839973, encodeId=f02c18399e366, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Tue Nov 15 09:06:53 CST 2022, time=2022-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034297, encodeId=8d91203429e28, content=<a href='/topic/show?id=33d28e81604' target=_blank style='color:#2F92EE;'>#药物疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87816, encryptionId=33d28e81604, topicName=药物疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db5b227, createdName=gostraight, createdTime=Sun Sep 18 06:06:53 CST 2022, time=2022-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897022, encodeId=bea6189e0223d, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Tue Jul 26 18:06:53 CST 2022, time=2022-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286113, encodeId=660612861131d, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Jun 18 20:06:53 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226954, encodeId=a45d1226954c7, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Fri Jun 17 07:05:45 CST 2022, time=2022-06-17, status=1, ipAttribution=)]
    2022-06-17 学医无涯

    学习一下

    0

相关资讯

盘点2017-2021年美国FDA批准的抗肿瘤新药

随着科学的进步和医学的发展,放/化疗、小分子靶向药物、抗体药物、细胞疗法等一代又一代的创新疗法相继问世,癌症治疗已迈向“精准治疗”新时代。

如何与FDA合作以取得临床试验的成功?

新药的开发,尤其是近年处于热潮的罕见疾病药物开发,临床开发阶段加强与监管机构的沟通必不可少。本文以Timber制药公司的案例,简要为大家介绍这家制药公司如何与FDA合作,以取得新药开发临床试验成功。

FDA:2022年第一季度批准十款创新药上市!

本文内容大多参考FDA官方的药物说明书,部分数据参考发表文献,或者摘取自维基百科及药企官方公告,图片来源于药物官网或相关文献。

FDA批准多奈哌齐透皮贴剂获批用于治疗阿尔茨海默症

FDA Approved: Yes (First approved March 11, 2022)

FDA批准骨髓纤维化新药pacritinib

批准日期:2022年2月28日

不用被捅了,FDA紧急授权首个新冠呼吸检测平台,吹口气,三分钟出结果

人们只需要在一个经过培训的操作员的引导下,通过一次性吸管吹气,即可由设备完成呼吸样本的收集和检测,不到3分钟即可获取检测结果。

Baidu
map
Baidu
map
Baidu
map